Taiwan Innovation Board Eases Requirements: NT$1 Billion Market Cap and a One-Year Transfer Period
Storage information
Bookmarks and reading positions are stored in this browser. Manage and back them up in My Reading.
Collected in Robin Shen’s Field Notes · Content type and attribution are shown above
English translation of the Chinese post originally published 2022-09-21. Translated 2026-10-28 with AI assistance. Historical figures and claims have not been updated or independently verified. 中文原文
Reading guide
The Taiwan Innovation Board substantially relaxed its listing requirements: the first category’s minimum market capitalization fell from NT$1.5 billion to NT$1 billion, and its revenue requirement for the latest four quarters fell from NT$150 million to NT$100 million. The second, biomedical category’s market-cap threshold dropped from NT$3 billion to NT$2 billion; the third remained at NT$4 billion. The waiting period to apply for a board transfer shortened from two years after listing to one. A record of regulatory easing in Taiwan’s capital markets, as of September 2022.
Key points
- First-category market cap: NT$1.5 billion → NT$1 billion; revenue: NT$150 million → NT$100 million.
- Biomedical category: NT$3 billion → NT$2 billion.
- Board-transfer waiting period: two years → one year.
- Regulatory easing as of September 2022.
Full text — English translation
These articles are personal notes, book excerpts, and collected reprints. Figures and events reflect the time of the original publication, are not current information, and do not constitute investment advice.
DISCUSSION
Reader comments
What did this article make you think about? Different perspectives and constructive criticism are welcome.
Comments are public immediately. Do not include personal contact details or external links. Automated checks block suspicious solicitation, prohibited transactions and spam; they can make mistakes.
Comments load when you reach this section.
Administrator sign-in Sign out